Advertisement

Novartis has decided to halt sales of its approved high-blood pressure drug Rasilez, also called Tekturna, withdrawing the drug when used in combination with an ACE-inhibitor or ARB, due to side effects including non-fatal stroke, renal complications, hyperkalemia and hypotension. The side effects were discovered in a large, late-stage trial designed to gain approval for wider use, a spokeswoman said.

SOURCE

Advertisement
Advertisement